Whitney Burnley counsels clients on corporate and securities issues including mergers and acquisitions, capital markets transactions, and securities regulations matters and filings.
Whitney earned her law degree from the University of Memphis Cecil C. Humphreys School of Law and a B.S. in business administration from the University of Tennessee.
American Health Law Association (AHLA)
Representation of Triple Tree Capital Partners and Vestar Capital Partners in the merger of their respective portfolio companies, The Emily Program and Veritas Collaborative.
Representation of Louisiana-Pacific Corporation in its offering of $350,000,000 of 3.625% senior notes due 2029.
Representation of Regent Surgical Health, an ambulatory surgery center management and development company, in its strategic investment from TowerBrook Capital Partners L.P., an international investment management firm, and Ascension Capital, an investment affiliate of Ascension.
Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000.
Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000. B. Riley Securities acted as book-running manager and Lake Street Capital Markets, LLC acted as co-manager for the offering.
Representation of Premise Health, the largest direct health care provider in the country and OMERS portfolio company, in its acquisition of Sonic Boom Wellness, a provider of corporate wellness technology
We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the brain, in its $17.5 million strategic investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management, with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. With the net proceeds from the sale of the notes to PTC and Petrichor, the ClearPoint Neuro intends to repay in full its existing secured indebtedness, and to fund product commercialization, internal research and development, and general corporate requirements. Additionally, we advised ClearPoint Neuro in the draw of $7.5 million additional proceeds from Petrichor in December 2020. ClearPoint Neuro intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.
Representation of OptionOne, a specialty pharmacy providing home and alternate-site infusion therapies through a comprehensive clinical approach to patient care, in its sale to Amerita, Inc., a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. Terms of the transaction were not disclosed.
The University of Memphis Law Review — Editor-in-Chief, Volume 49; Staff Member, Volume 48
University of Memphis Cecil C. Humphreys School of Law Writing Center — Writing Fellow
Dean’s Distinguished Service Award
Dean’s Award for Excellence — Best Memorandum, Best Brief, and Best Oral Advocate
CALI Excellence for the Future Award — Property I
The University of Memphis Law Review — Best Note Award (2019)